Autophagy Modulation in Cisplatin-Resistant Gastric Cancer

Key Takeaways

• • Autophagy modulation is emerging as a promising strategy to overcome cisplatin-resistant gastric cancer.
  • Researchers identified several existing drugs and natural compounds that may improve chemotherapy response by targeting autophagy.
  • Combining autophagy-targeted therapies with immunotherapy, radiotherapy, and precision medicine could improve outcomes for patients with treatment-resistant gastric cancer.
  • Molecular targets, including signaling pathways, microRNAs, and transcription factors, may support the development of personalized cancer therapies.
  • Explore All Oncology CME Conferences & Online Courses

Autophagy Modulation in Cisplatin-Resistant Gastric Cancer: A New Therapeutic Strategy

Drug resistance remains a major challenge in the treatment of cisplatin-resistant gastric cancer, limiting the long-term success of one of the most widely used chemotherapy agents for advanced gastric malignancies. A recent review highlights autophagy modulation as a promising therapeutic approach that could improve chemotherapy sensitivity and reduce resistance, offering new opportunities for oncologists managing difficult-to-treat cases.

Autophagy is a natural cellular process that removes damaged proteins and organelles while maintaining cellular balance. In gastric cancer, however, this process has a complex role. Depending on the tumor environment, autophagy may either protect cancer cells from chemotherapy or contribute to their destruction. This dual function makes careful regulation of autophagy an important area of investigation for improving treatment outcomes.

How Can Autophagy Modulation Improve Cisplatin Response?

The review explains that cisplatin resistance develops through multiple biological mechanisms, including enhanced DNA repair, reduced apoptosis, alterations in the tumor microenvironment, and changes in cellular signaling pathways. Increasing evidence suggests that autophagy interacts with many of these resistance mechanisms, making it an attractive therapeutic target.

Researchers summarized evidence supporting several approved medications that may improve cisplatin effectiveness by regulating autophagy. These include diclofenac, metformin, chloroquine, omeprazole, ubenimex, and bortezomib. Depending on the biological context, these agents may either stimulate cancer-killing autophagy or suppress the protective form of autophagy that enables tumor survival during chemotherapy.

The review also highlights natural compounds such as glycyrrhizin, baicalein, red ginseng polysaccharide, and α-mangosteen as potential candidates for combination therapy. Although many findings remain in the preclinical stage, these compounds continue to generate interest for their ability to influence autophagy-related pathways.

What Molecular Targets Could Shape Future Gastric Cancer Therapies?

Beyond drug-based approaches, researchers identified several molecular regulators of autophagy, including signaling pathways, transcription factors, microRNAs, and proteins involved in tumor survival. These targets may support the development of precision therapies designed to restore chemotherapy sensitivity while limiting further resistance.

The review also emphasizes the value of combining autophagy modulation with immunotherapy, radiotherapy, and precision oncology strategies. Matching treatment to the biological characteristics of individual tumors may improve outcomes for patients whose cancers no longer respond to conventional chemotherapy.

Explore All Oncology CME Conferences & Online Courses

As research continues, autophagy-targeted therapies could become an important addition to the treatment landscape for cisplatin-resistant gastric cancer. Further clinical studies will determine how these strategies can be integrated into routine oncology practice and whether they can deliver more durable responses for patients facing chemotherapy resistance.

Source:

Compuscript Ltd